

# Rwanda Impact, Year-End 2011

In 2011, PSI averted an estimated 109,940 DALYs in Rwanda. This is a 69% decrease in DALYs averted compared to 2010.



## Platform Profile

Population	10,624,005
Population aged 0-5	1,830,654
Women aged 15-49	2,622,084
# Platform interventions	10
# Family planning interventions	5 with 1 LTM
Contraceptive prevalence	26.1% (2008)
* Population data from UN Population Division	

## RWANDA STRATEGIC PERFORMANCE

	2011	% Change from 2010	% Change from 2006	CAGR*** 2006 - 2011
<b>SCALE</b>				
■ DALYs Averted	109,940	-69%	-78%	-26%
■ Couple Years of Protection (CYP)*	124,439	4%	48%	8%
■ PSI Burden Averted	2.0%			
<b>RELEVANCE</b>				
■ Health Relevance	45%			
■ Family Planning Method Mix**	5 with 1 LTM			

\* CYPs based on new USAID conversion factors, except IUDs



\*\* Target is 4 or more FP modern methods with at least one long-term method

\*\*\* Compounded annual growth rate

## RWANDA HEALTH AREA PERFORMANCE

Current PSI Product & Service Health Areas	2011 DALYs Averted	% Change from 2010	% Change from 2006	2006-2011 DALY Trends	Burden Averted	% of Rwanda Burden
HIV & STD	56,933	-2%	29%		9.3%	11.2%
Reproductive Health	26,551	3%	47%		2.8%	17.1%
Malaria	14,961	-94%	-97%		5.4%	5.1%
Diarrheal Diseases	11,495	7%	-3317%		1.8%	11.7%
Potential 24% increase in relevance with expansion of existing PSI products and services						% of Rwanda Burden
Tuberculosis						3.5%
Intestinal Nematode Infections						0.2%
Nutritional Deficiencies						4.3%
Respiratory Infections						15.9%

## RWANDA TREND IN DALYS AND CYPs 2006-2011



## RWANDA PRODUCTS & SERVICES DALYS (from highest to lowest DALYs)

Products	2011 DALYs Averted	% Change from 2010	% Change from 2006	2011 # Distributed	2011 unit COGS*	2011 CYPs
Condom	79,830	1%	32%	13,233,068	\$0.04	110,276
Malaria PPT (ACT)	14,958	-62%	***	411,045	\$0.42	
Safe Water Solution	11,187	4%	-3230%	611,775	\$0.19	
VCT	908	-59%	-46%	36,485	\$0.95	
SDM (Cycle Beads)	853	8%	***	2,477	\$0.93	3,716
Injectable 3	706	-32%	105954%	13,787	\$0.73	3,447
OC	667	77%	463%	47,386	\$0.36	3,159
Implant 5 Distribution	519	**	***	1,011	\$21.20	3,842
PUR	308	**	***	1,683,686	\$0.04	
LLIN	3	-100%	-100%	14	\$4.24	
<b>Total</b>	<b>109,940</b>	<b>-69%</b>	<b>-78%</b>	<b>16,040,734</b>		<b>124,439</b>

\* Preliminary cost data

\*\* Product was not distributed in 2010

\*\*\* Product was not distributed in 2006

## PSI RELEVANCE: 2011 DALYS AVERTED COMPARED TO BURDEN OF DISEASE (WHO 2004)\*

